Ind Swift Laboratories Ltd Stock Price Today (NSE: INDSWFTLAB)
Fundamental Score
Ind Swift Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ind Swift Laboratories Ltd share price today is ₹162.10, down 1.27% on NSE/BSE as of 18 June 2026. Ind Swift Laboratories Ltd (INDSWFTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹787.55 (Cr). The 52-week high for INDSWFTLAB share price is ₹173.25 and the 52-week low is ₹87.15. At a P/E ratio of 26.57x, INDSWFTLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 0.18% and a debt-to-equity ratio of 0.02.
Ind Swift Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Ind Swift Laboratories Ltd share price chart: 0.39% return over the past month. 52-week high ₹173.25, 52-week low ₹87.15.
Ind Swift Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹165.00 | ₹167.74 | ₹160.80 | ₹162.10 | 15.72L (Cr) | |
| ₹154.00 | ₹173.25 | ₹153.13 | ₹164.19 | 62.80L (Cr) | |
| ₹138.00 | ₹161.00 | ₹138.00 | ₹152.11 | 73.65L (Cr) | |
| ₹134.83 | ₹134.83 | ₹134.83 | ₹134.83 | 0.00 (Cr) | |
| ₹136.50 | ₹138.28 | ₹133.30 | ₹134.83 | 7.42L (Cr) | |
| ₹132.00 | ₹137.21 | ₹130.00 | ₹136.17 | 6.90L (Cr) | |
| ₹132.80 | ₹135.90 | ₹129.50 | ₹132.18 | 6.27L (Cr) | |
| ₹135.45 | ₹136.04 | ₹131.00 | ₹131.79 | 6.23L (Cr) | |
| ₹137.45 | ₹138.00 | ₹134.99 | ₹135.35 | 1.52L (Cr) | |
| ₹134.10 | ₹139.14 | ₹132.46 | ₹135.88 | 3.39L (Cr) |
Ind Swift Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹154.00 | ₹173.25 | ₹153.13 | ₹162.10 | +5.26% | |
| ₹138.11 | ₹161.00 | ₹129.31 | ₹152.11 | +10.14% | |
| ₹135.00 | ₹156.80 | ₹127.30 | ₹137.54 | +1.88% | |
| ₹138.00 | ₹151.51 | ₹126.00 | ₹131.43 | -4.76% | |
| ₹112.90 | ₹151.98 | ₹106.23 | ₹145.33 | +28.72% | |
| ₹89.24 | ₹117.80 | ₹87.25 | ₹113.41 | +27.08% | |
| ₹97.00 | ₹99.50 | ₹87.15 | ₹88.15 | -9.12% | |
| ₹102.71 | ₹106.50 | ₹93.00 | ₹97.48 | -5.09% | |
| ₹97.20 | ₹112.50 | ₹94.00 | ₹102.71 | +5.67% | |
| ₹97.00 | ₹112.70 | ₹94.71 | ₹95.23 | -1.82% | |
| ₹106.00 | ₹110.25 | ₹92.70 | ₹96.06 | -9.38% | |
| ₹112.90 | ₹124.00 | ₹101.00 | ₹105.00 | -7.00% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ind Swift Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ind Swift Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDSWFTLAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (16.66%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (1848.78%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (1176.25%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (15.79% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (15.81% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹148.79 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (0.18%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.78%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-6.35% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (1.17x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ind Swift Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ind Swift Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ind Swift Laboratories LtdInd Swift Labor...Selected✓ INDSWFTLAB • 532305 | 42.2/100 | ₹162.10₹162 | ₹787.55₹787.55 | 26.57Average 26.6 Average | 0.18%Poor 0.18% Poor | 0.78%Poor 0.78% Poor | 0.02Excellent 0.0 Excellent | 15.81%Excellent 15.81% Excellent | -6.35%Poor -6.35% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Ind Swift Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for INDSWFTLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹71.24 | ₹108.57 | 1.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ind Swift Laboratories Ltd Quarterly Performance
Latest quarterly metrics for INDSWFTLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
1176.25%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1848.78%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-6.35%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.81%
Compounded annual net profit growth over 5 years
Ind Swift Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INDSWFTLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ind Swift Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Ind Swift Laboratories Ltd (INDSWFTLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ind Swift Laboratories Ltd
About INDSWFTLAB (Ind Swift Laboratories Ltd)
Ind Swift Laboratories Ltd is a dynamic pharmaceutical entity carving its niche in the global healthcare landscape. With a steadfast commitment to innovation and quality, the compa...ny dedicates its resources to the research, development, and production of a diverse portfolio of pharmaceutical products. Its activities are deeply rooted in scientific rigor, with a focus on creating effective and accessible medications for a range of therapeutic needs. By combining advanced technologies and skilled personnel, Ind Swift Laboratories strives to address pressing health challenges and improve patient outcomes worldwide. The company stands as a testament to the power of dedicated pharmaceutical research in improving global health. The core business of Ind Swift Laboratories revolves around the creation of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished formulations, contributing to a comprehensive approach to drug development and manufacturing. The company strategically markets these products both domestically and internationally, reaching healthcare providers and patients across different regions. They have a strong emphasis on the manufacturing process, as the creation of APIs requires the utmost control. They're committed to high quality ingredients to ensure the safety and efficacy of its medicinal products. Ind Swift Laboratories is not just producing pharmaceuticals, but rather, is actively contributing to global healthcare solutions through its expanded reach and market strategy. Ind Swift Laboratories' dedication goes beyond simple manufacturing; they operate as an innovative force, pushing the boundaries of pharmaceutical science. This commitment is evident in its expanding portfolio of APIs, which caters to a broad spectrum of therapeutic areas. This includes treatments for cardiovascular conditions, diabetes, and a host of other ailments, demonstrating its commitment to addressing a wide range of health concerns. Through tireless effort and a focus on continuous improvement, Ind Swift Laboratories seeks to develop novel solutions that contribute to a healthier future. This dedication to improving the lives of individuals through innovative pharmaceuticals is the driving force behind Ind Swift Laboratories' growth and success.
Company Details
Key Leadership
Corporate Events
INDSWFTLAB Share Price: Frequently Asked Questions
What is the current share price of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd (INDSWFTLAB) trades at ₹162.10 on NSE and BSE. Market cap ₹787.55 (Cr). Educational data only.
What is the P/E ratio of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has a P/E of 26.57x vs industry average 31.77x.
What is the Bull Run score for Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has a Bull Run score of 42.2/100 based on 25+ financial parameters.
Does Ind Swift Laboratories Ltd pay dividends?
Ind Swift Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has ROE of 0.18%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has debt-to-equity of 0.02.
Is Ind Swift Laboratories Ltd a good investment?
Bull Run gives Ind Swift Laboratories Ltd a score of 42.2/100. This is not investment advice — consult a SEBI-registered advisor.